Literature DB >> 12740673

Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities.

V Riccieri1, T Rinaldi, A Spadaro, R Scrivo, F Ceccarelli, M Di Franco, E Taccari, G Valesini.   

Abstract

The aim of this study was to investigate whether interleukin-13 (IL-13) serum levels correlate to different nailfold capillaroscopy (NC) findings in patients with systemic sclerosis (SSc). IL-13 serum levels were measured using an ELISA method. The following NC abnormalities were considered: the presence of giant loops, haemorrhages, loss of capillaries, disorganisation of the vascular array, ramified/bushy capillaries and sludging of blood. A semiquantitative rating scale was adopted to score these changes, as well as a rating system for avascular areas and three morphological NC patterns ('early', 'active' and 'late'). Mean capillary density was determined by counting the total number of capillaries in a 1 mm length, and the arterial and venous diameters of the capillary as well as the total loop diameter were measured. In SSc patients IL-13 serum levels were significantly higher than in controls ( P < 00.1), whereas in patients with ( n=8) and without ( n=24) abnormal IL-13 serum levels (>17 pg/ml) the comparison of the NC features showed significantly relevant differences concerning a more frequent 'active' NC pattern ( P < 0.02), the presence of haemorrhages ( P < 0.0037) and sludging of blood ( P < 0.038), as well as larger total loop ( P < 0.036) and arterial ( P < 0.03) diameters, in those patients with elevated IL-13 serum levels. The study confirmed that IL-13 serum levels are higher in the sera of patients with SSc, and shows for the first time the significant correlations between this serological finding and some of the main relevant SSc capillaroscopic features, leading us to believe that this cytokine not only seems to sustain the immunological and fibrotic process of SSc, but might have a role in determining the more severe microvascular lesions in this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740673     DOI: 10.1007/s10067-002-0684-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis.

Authors:  Thomas M Chiang; Arnold E Postlethwaite
Journal:  Biochim Biophys Acta       Date:  2007-04-18

Review 2.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 3.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 4.  Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.

Authors:  Xiao-Lei Huang; Yu-Jie Wang; Jun-Wei Yan; Ya-Nan Wan; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflamm Res       Date:  2015-03-01       Impact factor: 4.575

Review 5.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

6.  Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.

Authors:  Bart van Hartingsveldt; Ivo P Nnane; Esther Bouman-Thio; Matthew J Loza; Alexa Piantone; Hugh M Davis; Kevin J Petty
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

7.  Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.

Authors:  Matthew B Greenblatt; Jennifer L Sargent; Giuseppina Farina; Kelly Tsang; Robert Lafyatis; Laurie H Glimcher; Michael L Whitfield; Antonios O Aliprantis
Journal:  Am J Pathol       Date:  2012-01-11       Impact factor: 4.307

8.  Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.

Authors:  Monique Hinchcliff; Diana M Toledo; Jaclyn N Taroni; Tammara A Wood; Jennifer M Franks; Michael S Ball; Aileen Hoffmann; Sapna M Amin; Ainah U Tan; Kevin Tom; Yolanda Nesbeth; Jungwha Lee; Madeleine Ma; Kathleen Aren; Mary A Carns; Patricia A Pioli; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

9.  Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects.

Authors:  Antonio Aversa; Roberto Bruzziches; Davide Francomano; Edoardo Rosato; Felice Salsano; Giovanni Spera
Journal:  Int J Rheumatol       Date:  2010-10-05

10.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors:  Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Journal:  Arthritis Res Ther       Date:  2010-07-05       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.